MEI Pharma Files Q2 2025 10-Q
Ticker: LITS · Form: 10-Q · Filed: Feb 12, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 10-Q |
| Filed Date | Feb 12, 2025 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.00000002 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financials
TL;DR
MEI Pharma dropped its Q2 2025 10-Q. Check financials.
AI Summary
MEI Pharma, Inc. filed its 10-Q for the period ending December 31, 2024, reporting on its financial performance for the second quarter. The company's fiscal year ends on June 30th. Key financial data and operational details for the period are presented in this filing.
Why It Matters
This filing provides investors with an update on MEI Pharma's financial health and operational progress, crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, MEI Pharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Period End Date (Latest reported quarter)
- 2023-12-31 — Prior Year Quarter End Date (Comparison period)
Key Players & Entities
- MEI Pharma, Inc. (company) — Filer
- 20241231 (date) — Period of Report
- 20250212 (date) — Filing Date
- San Diego, CA (location) — Business Address
- BeiGene Ltd (company) — Partner/Licensee
- Presage Biosciences Inc (company) — Partner/Licensee
FAQ
What were MEI Pharma's revenue figures for the reported quarter and the comparable prior year period?
The filing indicates revenue from contracts with customers for the period 2023-10-01 to 2023-12-31, but specific dollar amounts for the current period are not detailed in the provided text.
What is the company's fiscal year end?
MEI Pharma's fiscal year ends on June 30th.
What is the company's primary business address?
The company's business address is 11455 El Camino Real, Suite 250, San Diego, CA 92130.
Are there any significant licensing agreements mentioned?
Yes, the filing mentions the Presage License Agreement with Presage Biosciences Inc.
What is the SEC file number for MEI Pharma?
The SEC file number for MEI Pharma is 001-41827.
Filing Stats: 4,379 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2025-02-12 16:00:20
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar
Filing Documents
- meip-20241231.htm (10-Q) — 1380KB
- meip-ex31_1.htm (EX-31.1) — 16KB
- meip-ex32_1.htm (EX-32.1) — 7KB
- img105009805_0.jpg (GRAPHIC) — 130KB
- 0000950170-25-018809.txt ( ) — 6573KB
- meip-20241231.xsd (EX-101.SCH) — 1141KB
- meip-20241231_htm.xml (XML) — 912KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 28 Item 4.
Controls and Procedures
Controls and Procedures 28 PART II OTHER INFORMATION 30 Item 1.
Legal Proceedings
Legal Proceedings 30 Item 1A.
Risk Factors
Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31
SIGNATURES
SIGNATURES 32 2 Table of Contents
FINANCIAL INFORMATION
PART I FINANCIAL INFORMATION
Condensed Consolidated Financial Statements
Item 1. Condensed Consolidated Financial Statements MEI PHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value data) December 31, June 30, 2024 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 23,739 $ 3,705 Short-term investments — 34,640 Prepaid expenses and other current assets 646 2,424 Total current assets 24,385 40,769 Operating lease right-of-use asset — 214 Property and equipment, net — 392 Total assets $ 24,385 $ 41,375 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 596 $ 3,168 Accrued liabilities 1,691 5,187 Total current liabilities 2,287 8,355 Total liabilities 2,287 8,355 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock, $ 0.01 par value; 100 shares authorized; no ne outstanding — — Common stock, $ 0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at December 31, 2024 and June 30, 2024. — — Additional paid-in capital 421,001 421,239 Accumulated deficit ( 398,903 ) ( 388,219 ) Total stockholders' equity 22,098 33,020 Total liabilities and stockholders' equity $ 24,385 $ 41,375 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents MEI PHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) For the Three Months Ended December 31, For the Six Months Ended December 31, 2024 2023 2024 2023 Revenues: Revenue from customers $ — $ — $ — $ 752 Revenue from collaboration agreements — — — 64,545 Total revenues — — — 65,297 Operating expenses: Research and development 308 3,912 3,471 7,397 General and administrative 3,143 8,018 8,332 14,549 Total operating expenses 3,451 11,930 11,803 21,946